ReviewEnvironmental epigenetics2020
Epigenetic biomarkers and preterm birth.
Review in Environmental epigenetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Mitochondrial dysfunction in neonatal brain injury: from molecular mechanisms to therapeutic interventions.Journal of translational medicine · 2026Review
- Epigenetic signatures of maternal-fetal health: insights from cord blood and placenta.Epigenetics · 2025Article
- Placental DNA methylation key topics: sex- and cell-type specificity, mediation, multi-omics, and biomarker discovery.Epigenomics · 2025Review
- Cost-effective promoter methylation analysis via target long-read bisulfite sequencing: a case study in severe preterm birth.BMC medical genomics · 2025Article
- Sex Differences in Hypertension Risk: Insights from Placental Genomics and Pregnancy-Driven Vascular Programming.International journal of molecular sciences · 2025Review
- Article
- The impact of DNA methylation as a factor of Adverse Pregnancy and Birth Outcomes (APBOs): a systematic review protocol.Systematic reviews · 2024Article
- Melatonin: the placental antioxidant and anti-inflammatory.Frontiers in immunology · 2024Review
- First Trimester Prediction of Preterm Birth in Patient Plasma with Machine-Learning-Guided Raman Spectroscopy and Metabolomics.ACS applied materials & interfaces · 2023Article
- Advances in Genetics and Epigenetics of Developmental Coordination Disorder in Children.Brain sciences · 2023Review
- Genetics, epigenetics, and transcriptomics of preterm birth.American journal of reproductive immunology (New York, N.Y. : 1989) · 2022Review
- The contribution of racism-related stress and adversity to disparities in birth outcomes: evidence and research recommendations.F&S reports · 2022Article
- The emergence of developmental behavioral epigenomics.Epigenomics · 2022Article
- Preterm birth buccal cell epigenetic biomarkers to facilitate preventative medicine.Scientific reports · 2022Article
- Expression and role of anti-oxidative damage factors in the placenta of preterm infants with premature rupture of membranes.Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2022Article
- Using primary teeth and archived dried spots for exposomic studies in children: Exploring new paths in the environmental epidemiology of pediatric cancer.BioEssays : news and reviews in molecular, cellular and developmental biology · 2021Review
- Conducting epigenetics research with refugees and asylum seekers: attending to the ethical challenges.Clinical epigenetics · 2021Review
- Adiponectin as a Potential Biomarker for Pregnancy Disorders.International journal of molecular sciences · 2021Review
- Leveraging biosocial methods to examine and address structural determinants of health and promote health equity.Nursing outlookArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Preterm birth (PTB) is a major public health challenge, and novel, sensitive approaches to predict PTB are still evolving. Epigenomic markers are being explored as biomarkers of PTB because of their molecular stability compared to gene expression. This approach is also relatively new compared to gene-based diagnostics, which relies on mutations or single nucleotide polymorphisms. The fundamental principle of epigenome diagnostics is that epigenetic reprogramming in the target tissue (e.g. placental tissue) might be captured by more accessible surrogate tissue (e.g. blood) using biochemical epigenome assays on circulating DNA that incorporate methylation, histone modifications, nucleosome positioning, and/or chromatin accessibility. Epigenomic-based biomarkers may hold great potential for early identification of the majority of PTBs that are not associated with genetic variants or mutations. In this review, we discuss recent advances made in the development of epigenome assays focusing on its potential exploration for association and prediction of PTB. We also summarize population-level cohort studies conducted in the USA and globally that provide opportunities for genetic and epigenetic marker development for PTB. In addition, we summarize publicly available epigenome resources and published PTB studies. We particularly focus on ongoing genome-wide DNA methylation and epigenome-wide association studies. Finally, we review the limitations of current research, the importance of establishing a comprehensive biobank, and possible directions for future studies in identifying effective epigenome biomarkers to enhance health outcomes for pregnant women at risk of PTB and their infants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.